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Patients (or Materials) and Methods: Patients treated with DRV for 
HIV infection were enrolled in this study. Efficacy of drug therapy 
was evaluated by relative change of copy number of HIV in blood, 
and the blood samples were taken when the relative copy number of 
< 200 copies/mL. The concentrations of DRV in plasma and PBMC 
were analyzed using HPLC-fluorescence detection method. Then, in 
vitro uptake study using human leukemia cell line, MOLT-4, was 
performed. The intracellular concentrations of DRV were measured 
after exposure to DRV (3.0 μ g/mL in medium) or the combination 
of DRV and ritnavir (RTV) (3.0 and 1.0 μ g/mL in medium, respec-
tively) for 2 hours.
Results: The effective concentrations of DRV in plasma showed 
great variation of 0.88 to 5.57 μ g/mL, while the concentrations 
in PBMC were maintained within a relatively-narrow range 12.9–
28.7ng/106 cells. In in vitro study, RTV, a P-gp inhibitor, significantly 
increase the intracellular concentration of DRV (10.0 vs 15.9 ng/106 
cells).
Conclusion: Our results suggested that the concentration of DRV 
in PBMC could be better indicator for clinical efficacy of DRV com-
pared with that in plasma. In in vitro study, we found that RTV could 
promote the intracellular accumulation of DRV, and it was thought 
to be due to the P-gp inhibitory activity of RTV. Those results mean 
that coadministration of RTV have possibility to increase intracel-
lular concentration of DRV and result to sufficient clinical efficacy of 
DRV regardless the concentration of DRV in plasma.
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Introduction: Triazole antifungal agent voriconazole (VRCZ) 
has a nonlinear pharmacokinetics. VRCZ is extensively metabo-
lized hepatically to major inactive metabolites VRCZ N-oxide 
(VNO). Few clinical reports revealed the influence of VNO on the 
metabolic process of VRCZ. The present study aimed to evaluate 
metabolic process of VRCZ in patients taking plasma concentra-
tion of VNO.
Patients (or Materials) and Methods: Fifty-eight Japanese patients 
receiving oral or intravenous VRCZ for prophylaxis or fungal infec-
tions at Hamamatsu University Hospital were included in the study. 
Predose plasma concentrations of VRCZ and VNO were moni-
tored at day 5 or later. The relationships between plasma exposure 
parameters of VRCZ and VNO were evaluated. CYP2C19 genetic 
polymorphism (G636A and G681A on exon 4 and exon 5) were 
determined using PCR-RFLP method for assessing the influence of 
major metabolic enzyme of VRCZ.
Results: A large interindividual variation was observed in the plasma 
concentrations of VRCZ and VNO. Dose-normalized VRCZ con-
centration had a strong correlation with VRCZ concentration and a 
straight line passing through nearby the origin of the coordinates was 
obtained. No significant correlation between the plasma concentra-
tions of VRCZ and VNO was observed. Plasma concentration ratio 
of VRCZ to VNO (VRCZ/VNO) was strongly correlated with VRCZ 
concentration. No significant difference was observed in the plasma 
concentrations of VRCZ and VNO and VRCZ/VNO between the 
CYP2C19 genotypes.
Conclusion: Metabolic process of VRCZ to VNO is saturable in 
clinical dose range. Our findings indicated that nonlinear pharma-
cokinetics of VRCZ depends on its metabolic saturation
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Introduction: Retigabine (RTG)/ezogabine, N-[2-amino-4(4-
fluorobenzylamino)-phenyl] carbamic acid ethyl ester, is a novel 
antiepileptic compound. In 2011, RTG was approved by the FDA 
and European Commission as adjunctive treatment for partial onset 
seizures in adults aged ≥ 18 years. The global pivotal studies did not 
include Asian countries. The purpose of this study was to character-
ize the pharmacokinetics (PK) of single 50, 100, 200, and 400-mg 
doses of RTG and N-acetyl metabolites of RTG (NAMR) in healthy 
Taiwanese subjects.
Patients (or Materials) and Methods: Sixteen subjects were rand-
omized to the study (ANE116798, NCT01462669), which comprised 
a screening visit, 4 treatment periods, and a follow-up visit. The fol-
lowing PK parameters were determined for RTG and NAMR: Cmax, 
AUC0-inf, Tmax, and t½. Safety and tolerability were measured 
using adverse event (AE) reports, vital signs, electrocardiograms, clin-
ical laboratory measurements and Columbia Suicide Severity Rating 
Scale. Dose proportionality of RTG was assessed by fitting AUC0–inf 
and Cmax to a power model. A point estimate and 90% CI for the 
slope of the regression line obtained by regressing log(PK parameter) 
on log(dose) was calculated. As a secondary analysis, an analysis 
of variance was performed using loge-transformed dose-normalized 
AUC0–inf and Cmax by including periods and treatments as fixed 
effects and subjects as a random effect. All doses were compared with 
the 50 mg reference dose.
Results: Safety: No subject was withdrawn from the study owing to 
AEs and no serious AEs were reported. AEs reported most frequently 
in this population were somnolence, dizziness, and nausea, and the 
incidence of AEs increased with RTG dose. PK: Cmax value increases 
were approximately dose proportional from 50 to 100 mg, but less 
than dose proportional at 200 and 400 mg. AUC0–inf appeared 
to increase more than dose proportionally between 50 mg and the 
higher doses of 100, 200, and 400 mg. This was believed to be due 
to an underprediction of t½ at the 50-mg dose. AUC0–8, which 
represents the dosing interval of RTG with a 3-times-daily dosing 
regimen, was added as a post hoc PK parameter, since this truncated 
AUC is not confounded by determination of t½. AUC0–8 increased 
proportionally across the range of 50 to 400 mg.
Conclusion: Single oral doses of RTG (50–400 mg) were generally 
well tolerated in Taiwanese subjects. The PK parameters for RTG 
and NAMR in the current study in Taiwanese subjects are consistent 
with single-dose PK parameters obtained at these doses in healthy 
Western subjects.
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Introduction: Cachexia decreases CYP3A metabolism of oxycodone, 
while its influence on CYP2D6 metabolism remains to be clarified in 
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cancer patients. The aim of this study was evaluate the plasma con-
centrations of oxycodone and its demethylates and opioid-induced 
adverse effects based on cachexia stage in cancer patients receiving 
oxycodone.
Patients (or Materials) and Methods: Seventy patients receiving 
oxycodone for cancer pain at Hamamatsu University Hospital were 
enrolled. Cachexia was evaluated using the Glasgow Prognostic Score 
(GPS). Predose plasma concentrations of oxycodone, oxymorphone, 
and noroxycodone were determined at the titration dose. Opioid-
induced adverse effects were monitored for 2 weeks after the titra-
tion.
Results: Fourteen patients had a GPS of 0, 27 a GPS of 1, and 29 a 
GPS of 2. Plasma concentrations of oxycodone and oxymorphone 
but not noroxycodone in patients with a GPS of 2 were significantly 
higher than that with a GPS of 0. The metabolic ratios of noroxyco-
done but not oxymorphone to oxycodone in patients with a GPS of 1 
and 2 were significantly lower than in those with a GPS of 0. A higher 
GPS was associated with a higher incidence of somnolence, while 
the GPS did not affect the incidence of vomiting. Plasma concentra-
tions of oxycodone and oxymorphone were not associated with the 
incidence of adverse effects.
Conclusion: Cancer cachexia raised the plasma exposures of oxy-
codone and oxymorphone through the reduction of CYP3A but not 
CYP2D6. Although the cachexia elevated the incidence of somno-
lence, alterations in their pharmacokinetics were not associated with 
the incidence.
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Introduction: Many issues remain to be solved in regard to cannabi-
noid disposition, elimination time profiles and correlation between 
oral fluid (OF) and whole blood (WB) concentrations. Delta-9-
tetrahydrocannabinol (THC) in OF is usually indicative of a relatively 
recent cannabis exposure, but the study of other cannabinoids in OF 
and WB could also be helpful as a confirmatory test when applied 
for legal purposes.
Patients (or Materials) and Methods: A randomized, blinded, 2-way 
crossover study was conducted in 48 healthy volunteers (23 heavy 
and 25 occasional cannabis smokers) who received by smoking on 
each period, in random sequence, a cannabis joint (containing bed-
robinol, 11% THC, and traces of cannabidiol- CBD) or a placebo. 
WB was collected up to 2.5 hours after smoking. An additional WB 
sample at 3.5 hours, and OF samples were collected in heavy smok-
ers. Storage at –20°C and liquid-liquid extraction preceded analy-
sis by liquid chromatography-tandem mass spectrometry. THC, 
11-hydroxy-THC (11-OH-THC) and 11-nor-9-carboxy-THC 
(THCCOOH) were measured in WB. THC, THCCOOH, cannabi-
nol (CBN), CBD and delta-9-tetrahydrocannabinolic acid A (THC-A) 
were investigated in OF. WB pharmacokinetic parameters of THC 
and its metabolites were compared in heavy and occasional smokers. 
Correlations for these parameters between OF and WB were studied 
in heavy smokers.
Results: Before smoking, a significant difference (P < 0.001) was 
found in WB THCCOOH between heavy and occasional smokers: 
median THCCOOH was 20.1 µg/L (range, 2.50–93.9) and 0.14 µg/L 
(range, 0–16.6) respectively. No significant difference was found in 
WB for THC maximal concentrations (Cmax): median Cmax were 86.5 
µg/L (range, 37.1–192) and 75.1 µg/L (range, 8.20–168) respectively. 
Elimination half-lives (t1/2) in WB were also not significantly differ-
ent: median THC T1/2 were 0.97 hours (range, 0.55–1.87) and 0.84 
hour (range, 0.69–1.45) respectively; and median THCCOOH t1/2 
were 3.89 hours (range, 1.68–9.16) and 3.33 hours (range, 1.59–
17.3) respectively. Differences in the area under the curve (AUC) 
between both groups, were marginally significant for THC (P = 0.01) 
but highly significant (P < 0.001) for 11-OH-THC and THCCOOH. 
No correlation between WB and OF was found in heavy smokers for 
Cmax or AUC.
Conclusion: Our results suggest that the smoking regimen (heavy/
occasional) do not influence the elimination kinetic of cannabinoids 
in WB but do influence the initial THCCOOH level. No correlation 
was found between WB and OF for THC or THCCOOH parameters.
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Introduction: Methadone is known to be associated with pro-
longation of corrected QT time (QTc). Excretion of methadone 
is primarily renal in patients with normal renal function. It is 
unknown to what extent hemodialysis removes methadone. We 
investigated methadone kinetics and QTc during hemodialysis 
in methadone maintenance treatment (MMT) patients with end-
stage renal disease.
Patients (or Materials) and Methods: The Regional Ethics 
Committee approved the study. Data are given as median (range). 
Four patients with end-stage renal failure, 1 female and 3 males, 46 
(43–53) years, stabilized on methadone were included. Methadone 
was measured by UPLC-MMS in serum and hemodialysates col-
lected before morning methadone intake, every 30 minutes during 4 
hours hemodialysis and before afternoon dose, and in urine sampled 
at the end of hemodialysis. ECGs were recorded every 30 minutes 
during hemodialysis, and QT time was measured in lead v2 using 
tangential method and QTc was calculated with Bazzet’s formula. 
ECGs were read serially for each patient with blinding of number-
ing. Several routine biochemical tests were performed before and 
after hemodialysis.
Results: The daily methadone dose was 100 (60–120) mg. Serum-
methadone increased from Cmin of 1124 (547–1581) nmol/L to 
Cmax of 1806 (1237–2098) nmol/l after 85 (40–120) minutes. The 
apparent half-life of methadone was 12 (6.3–25) hours. A total of 
2.30 (1.25–3.70) % and 0.14 (0.03–0.26) % of daily methadone 
intake was collected, respectively, in hemodialysate and urine dur-
ing 4 hours. Renal clearance of methadone was 0.67 (0.31–1.20) 
mL/min, methadone clearance of hemodialysis was 17.10 (13.67–
20.61) mL/min and AUC of dose interval was 253.5 mg min/L. QTc 
increased from 395 (369–406) ms to 452 (407–479) ms with P = 
0.068,Wilcoxon paired comparison. The maximum QTc occurred 
